Patients with CHF and LV systolic dysfunction should receive guideline-directed medical therapy, i.e. ACE-I/ARB/angiotensin receptor-neprolysin inhibitor (ARNI), sodium-glucose cotransporter-2 (SGLT2) inhibitor, beta blocker (BB), and mineralocorticoid receptor antagonist (MRA) as tolerated. Here, SLC5A2 is linked to congestive heart failure.